Hormone receptor positive HER2 negative breast cancer
Not recruitingStudy Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression
Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:CapecitabinePaclitaxel+2
France- Participants:18–64 years · 65+ years
- Substances:Capecitabine
